Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and convergent mechanisms of regulation in diabetes
Version 2 2024-06-04, 15:41Version 2 2024-06-04, 15:41
Version 1 2018-08-31, 14:45Version 1 2018-08-31, 14:45
journal contribution
posted on 2024-06-04, 15:41 authored by H Rafehi, A Kaspi, Mark ZiemannMark Ziemann, J Okabe, TC Karagiannis, A El-OstaSystems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and convergent mechanisms of regulation in diabetes
History
Journal
EpigeneticsVolume
12Pagination
991-1003Location
United StatesOpen access
- Yes
ISSN
1559-2294eISSN
1559-2308Language
EnglishPublication classification
C Journal article, C1.1 Refereed article in a scholarly journalCopyright notice
2017, Taylor & Francis GroupIssue
11Publisher
TAYLOR & FRANCIS INCUsage metrics
Categories
Keywords
Science & TechnologyLife Sciences & BiomedicineBiochemistry & Molecular BiologyGenetics & HeredityepigenomicsHDAC inhibitorsmeta-analysisSAHAhistone acetylationdiabetesendothelial dysfunctionnetwork analysispathway analysiscomputation biologyHISTONE DEACETYLASE INHIBITORSCARDIAC-HYPERTROPHYINSULIN-RESISTANCEP300 AUTOACETYLATIONGENOMIC FEATURESEXPRESSIONTRANSCRIPTOMEINFLAMMATIONACTIVATIONDISORDERSSchool of Life and Environmental Sciences3101 Biochemistry and cell biology3105 Genetics3208 Medical physiology
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC